2024-513845-36-00CompletedPhase 1
Evaluation of vamorolone CYP3A4 induction on midazolam (a sensitive CYP3A4 substrate) pharmacokinetics
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Aug 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 7 Jun 2024
- Start date
- 13 Aug 2024
- Lead sponsor
- Santhera Pharmaceuticals (Schweiz) AG
- Diseases
- Duchenne muscular dystrophy
- EU CT number
- 2024-513845-36-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 18
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nuvisan GmbH | Neu-Ulm | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.